These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2701779)

  • 1. Parkinson's disease: positron emission tomographic studies.
    Martin WR
    Semin Neurol; 1989 Dec; 9(4):345-50. PubMed ID: 2701779
    [No Abstract]   [Full Text] [Related]  

  • 2. [Positron-emission tomographic studies of the brain in parkinsonism patients].
    Berezhkova LV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(6):93-7. PubMed ID: 8788992
    [No Abstract]   [Full Text] [Related]  

  • 3. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?
    Sawle GV
    Mov Disord; 1993 Jul; 8(3):271-7. PubMed ID: 8341290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebral perfusion and oxygen metabolism in Parkinson's disease: positron emission tomographic study using oxygen-15-labeled CO2 and O2].
    Tanaka M; Kondo S; Okamoto K; Hirai S
    Nihon Rinsho; 1997 Jan; 55(1):218-21. PubMed ID: 9014453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: metabolic and pharmacological approaches with positron emission tomography.
    Raichle ME; Perlmutter JS; Fox PT
    Ann Neurol; 1984; 15 Suppl():S131-2. PubMed ID: 6611113
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain glucose metabolism in Parkinson's disease.
    Metter EJ; Kuhl DE; Riege WH
    Adv Neurol; 1990; 53():135-9. PubMed ID: 2239454
    [No Abstract]   [Full Text] [Related]  

  • 7. 11C-WIN 35,428 for detecting dopamine depletion in mild Parkinson's disease.
    Madras BK
    Ann Neurol; 1994 Mar; 35(3):376-7. PubMed ID: 8122895
    [No Abstract]   [Full Text] [Related]  

  • 8. Positron emission tomography studies in parkinsonism.
    Eidelberg D
    Neurol Clin; 1992 May; 10(2):421-33. PubMed ID: 1584183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson's disease.
    Hägglund J; Aquilonius SM; Bergström K; Eckernäs SA; Hartvig P; Lundqvist H; Långström B; Malmborg P; Någren K
    Adv Neurol; 1987; 45():99-101. PubMed ID: 2950732
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current status of nuclear neuroimaging].
    Kuwabara Y
    Fukuoka Igaku Zasshi; 2003 Feb; 94(2):26-30. PubMed ID: 12728544
    [No Abstract]   [Full Text] [Related]  

  • 11. Positron emission tomography in movement disorders.
    Martin WR
    Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease.
    Kaasinen V; Rinne JO
    Neurosci Biobehav Rev; 2002 Nov; 26(7):785-93. PubMed ID: 12470690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic modeling of PET data: quantitative conflict and challenge.
    Ichise M; Ballinger JR
    J Nucl Med; 1997 Aug; 38(8):1266-7. PubMed ID: 9255162
    [No Abstract]   [Full Text] [Related]  

  • 14. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies arising from recent FDOPA articles.
    Cumming P; Gjedde A; Reith J
    J Nucl Med; 1997 Aug; 38(8):1267-71. PubMed ID: 9255163
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.
    Martin WR; Stoessl AJ; Adam MJ; Ammann W; Bergstrom M; Harrop R; Laihinen A; Rogers JG; Ruth TJ; Sayre CI
    Adv Neurol; 1987; 45():95-8. PubMed ID: 3103398
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 18. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
    Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Positron emission tomography. A new measurement method for imaging of regional and biochemical parameters].
    Bolwig TG; Haunsø S; Hove JD; Hesse B; Højgaard L; Jensen M; Paulson OB; Svendsen JH; Sørensen SS
    Ugeskr Laeger; 1994 Oct; 156(43):6341-7. PubMed ID: 7810006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.
    de la Fuente-Fernández R; Lu JQ; Sossi V; Jivan S; Schulzer M; Holden JE; Lee CS; Ruth TJ; Calne DB; Stoessl AJ
    Ann Neurol; 2001 Mar; 49(3):298-303. PubMed ID: 11261503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.